about us

Founded in 2001 with headquarters in Ann Arbor, Michigan, Adeona is a biotechnology company focused on the development of
synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses.

Adeona is focused on the development of synthetic biologics. To this end, the Company announced the formation of a global exclusive channel collaboration with the Human Therapeutics Division of Intrexon Corporation, through which Adeona intends to develop and commercialize a DNA-based therapeutic using Intrexon’s UltraVector® platform and RheoSwitch Therapeutic System® for the treatment of pulmonary arterial hypertension (PAH).

In addition, Adeona is developing, or has partnered the development of, funded programs to treat relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis (ALS).